Korjuny (Catumaxomab)

Korjuny is indicated for malignant ascites associated with EpCAM‑positive peritoneal carcinomatosis, a condition within the peritoneal cancer disease family.

• Malignant ascites: reduces fluid accumulation and improves patient comfort.
• Peritoneal carcinomatosis: targets and eliminates EpCAM‑expressing tumor cells within the peritoneal cavity.
• Quality of life: helps control symptoms related to ascitic buildup in affected patients.

• Catumaxomab is a bispecific monoclonal antibody that simultaneously binds EpCAM on tumor cells and CD3 on T lymphocytes. This dual binding creates an immunological synapse, activating T cells and triggering cytokine release, which leads to targeted tumor cell lysis and clearance from the peritoneal cavity.

Common Side Effects

• Fever: transient elevation of body temperature after administration.
• Abdominal pain: discomfort localized to the peritoneal area.
• Nausea and vomiting: gastrointestinal upset occurring shortly after dosing.
• Fatigue: generalized tiredness experienced during the treatment course.

Serious or Rare Side Effects

• Cytokine release syndrome: severe systemic inflammatory response requiring medical intervention.
• Hypotension: significant drop in blood pressure that may need monitoring.
• Severe allergic reactions: including anaphylaxis, urticaria or angioedema.

Precautions should be observed when using Korjuny to minimize risks and ensure optimal therapeutic outcomes.

• Cytokine release monitoring: observe patients for signs of systemic inflammation during and after infusion.
• Liver function assessment: evaluate hepatic enzymes before and during therapy.
• Immunosuppression caution: avoid use in patients with severe immunodeficiency.
• Cardiac disease awareness: monitor cardiovascular status in patients with pre‑existing heart conditions.
• Pregnancy and lactation: safety not established; use only if clearly needed.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions must be considered to avoid compromising safety or efficacy.

Major Interactions (Avoid)

• Concurrent immunomodulatory antibodies: may increase risk of severe immune reactions.
• Live vaccines: contraindicated due to immunosuppressive effects.
• High‑dose corticosteroids: can diminish therapeutic activity.

Moderate Interactions (Monitor Closely)

• Cytotoxic chemotherapy agents: monitor for additive toxicity.
• Antibiotics affecting gut flora: may alter infection risk.
• Anticoagulants: observe for bleeding tendencies.